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Abstract
Background: Quinolones are potent broad-spectrum bactericidal agents increasingly employed also in resource-limited
countries. Resistance to quinolones is an increasing problem, known to be strongly associated with quinolone exposure. We
report on the emergence of quinolone resistance in a very remote community in the Amazon forest, where quinolones have
never been used and quinolone resistance was absent in 2002.
Methods: The community exhibited a considerable level of geographical isolation, limited contact with the exterior and
minimal antibiotic use (not including quinolones). In December 2009, fecal carriage of antibiotic resistant Escherichia coli
was investigated in 120 of the 140 inhabitants, and in 48 animals reared in the community. All fluoroquinolone-resistant
isolates were genotyped and characterized for the mechanisms of plasmid- and chromosomal-mediated quinolone
resistance.
Principal Findings: Despite the characteristics of the community remained substantially unchanged during the period
2002–2009, carriage of quinolone-resistant E. coli was found to be common in 2009 both in humans (45% nalidixic acid, 14%
ciprofloxacin) and animals (54% nalidixic acid, 23% ciprofloxacin). Ciprofloxacin-resistant isolates of human and animal
origin showed multidrug resistance phenotypes, a high level of genetic heterogeneity, and a combination of GyrA
(Ser83Leu and Asp87Asn) and ParC (Ser80Ile) substitutions commonly observed in fluoroquinolone-resistant clinical isolates
of E. coli.
Conclusions: Remoteness and absence of antibiotic selective pressure did not protect the community from the remarkable
emergence of quinolone resistance in E. coli. Introduction of the resistant strains from antibiotic-exposed settings is the
most likely source, while persistence and dissemination in the absence of quinolone exposure is likely mostly related with
poor sanitation. Interventions aimed at reducing the spreading of resistant isolates (by improving sanitation and water/food
safety) are urgently needed to preserve the efficacy of quinolones in resource-limited countries, as control strategies based
only on antibiotic restriction policies are unlikely to succeed in those settings.
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Introduction
Quinolones are broad-spectrum antimicrobial agents with rapid
bactericidal activity, overall low toxicity, and the possibility of being
administered either orally or parenterally. Thanks to these features,
quinolones are drugs of choice for the treatment of several
community- and hospital-acquired infections (such as respiratory
tract infections, skin and soft-tissue infections, urinary tract
infections, gastro-intestinal infections, gonorrhea, tuberculosis,
etc.), being among the most prescribed antibiotics [1]. Moreover,
despite pediatric use has been restricted due to concerns with bone
cartilage toxicity, quinolones are increasingly prescribed also for the
treatment of life-threatening infections in pediatric patients [2,3].
Following the broad dissemination of pathogens with acquired
resistance to the older and less expensive antibiotics (e. g.
ampicillin, tetracycline and trimethoprim-sulfamethoxazole), and
PLOS Neglected Tropical Diseases | www.plosntds.org 1 August 2012 | Volume 6 | Issue 8 | e1790
the recent release of low-cost generic ciprofloxacin, the consump-
tion of quinolones has significantly increased also in resource-
limited countries [4,5]. In those settings, where the newest and
patent-protected antimicrobial compounds are not easily available,
quinolones have become key drugs for the treatment of common
bacterial infections, including those with a major impact in
morbidity and mortality, such as dysentery and typhoid fever
[6,7].
As observed with all other antimicrobial agents, also the
quinolones are affected by bacterial resistance. Acquired quino-
lone resistance has been reported among all major bacterial
pathogens, and has attained very high level rates in several
important Gram-positive and Gram-negative pathogens (including
Staphylococcus aureus, Neisseria gonorrhoeae, Escherichia coli, Klebsiella
pneumoniae, Salmonella enterica, Shigella spp., Pseudomonas aeruginosa,
Acinetobacter spp., Helicobacter pylori) in some settings [1,4–6,8–10].
Quinolone resistance generally arises in a stepwise manner,
following chromosomal mutations that alter the topoisomerase
targets or upregulate bacterial efflux systems. In Enterobacteriaceae,
several plasmid-mediated resistance mechanisms to quinolones
(PMQR) have also been detected, including the Qnr proteins (that
protect the topoisomerase targets), the AAC-cr enzyme (that
inactivates some quinolones by acetylation), and the QepA and
OqxAB efflux systems (which are able to extrude some quinolones)
[11]. Although these PMQR mechanisms are able to confer only
low level resistance to quinolones, their presence is thought to
facilitate the emergence of chromosomal mutations leading to
resistance levels of clinical significance [11].
A clear relationship has been demonstrated between the
emergence and dissemination of quinolone resistance among
bacterial pathogens and fluoroquinolone use, both in hospital and
community settings [5,12–14], while a recent study has also
reported a rapid decrease of quinolone resistance rates in clinical
isolates of E. coli after a countrywide intervention of quinolone
restriction [15]. The relationship between quinolone use and
resistance has also been indirectly supported by the absence or
very low rates of acquired resistance to these drugs in the few
studies which investigated antibiotic susceptibility in enterobacte-
ria isolated from humans or wild animals living in remote areas of
the planet away from anthropogenic drug exposure [16,17].
Here we report on the experience with a very remote
community of the Peruvian Amazon forest, where quinolone
resistance in commensal E. coli was found to be completely absent
in 2002 [18], but present at remarkable rates in 2009,
notwithstanding that during this period the community had
retained a condition of high level of geographical isolation, limited
exchanges with the exterior, minimal antibiotic exposure and
absence of quinolone availability.
Materials and Methods
Ethics Statement
Full ethical clearance was obtained from the qualified local
authorities who had revised and approved the study design and
consent form (Comite´ Institucional de E´tica de la Universidad
Peruana Cayetano Heredia, Lima, Peru). Before the fieldwork
started, representatives of the local healthcare authorities and the
research team met the community leader and adults to explain the
purpose and procedures of the survey.
All the inhabitants of the community were considered eligible
for the study. Prior to their enrollment, written informed consent
was obtained from all adult participants and from the parents or
legal guardians of minors. Any literate participant signed the
consent form. In case of an illiterate participant, the consent form
was read and signed by a witness (who was present throughout the
consent procedure and interview) and marked by the participant/
parent. Consent procedure and interviews were always conducted
by trained local healthcare workers with the help of a local
translator.
Study Design and Population
Angaiza is a community of Chayahuita ethnic group located in
the Alto Amazonas province of Peru. It was selected by the local
healthcare authorities as being one of the most isolated community
of the Peruvian Amazonas. In fact, from the nearest urban area
(Yurimaguas, about 32,000 inhabitants), Angaiza can be reached
by a 13-hour trip, including a 2-hour drive on an unpaved road
followed by a 4-hour motor boat ride and a final 7-hour walk in
the jungle. The population lives in typical Amazon huts including
a single room, without sanitation and electricity, and locally
collected rainwater represents the only water source. The principal
activities are agriculture, hunting and animal breeding (poultry,
pigs and cows). Healthcare available consists of the visits of a
professional healthcare worker approximately every 4 months, and
primary care for the most common illnesses provided by a
volunteer from the community.
A previous study on fecal carriage of antibiotic resistant
enterobacteria among the inhabitants of Angaiza was performed
in 2002 [18].
At the time of the 2009 survey, the Chayahuita community
comprised 140 individuals, living in 21 households. One hundred
twenty members of the community (86%) consented to participate
in the study (female-to-male ratio 61:59, age range 0–71 years,
mean age 17 years, median age 12 years) (Table 1). Study
participants were representative of all the 21 households of the
community (mean and median study participants per household
was 6 and 6, respectively).
The study was conducted during a two-day visit to the
community (December 12–13, 2009). Specially prepared forms
were used to collect data from the community leader (about the
Author Summary
Quinolones are broad-spectrum antibiotics which bind to
type II topoisomerases (DNA gyrase and topoisomerase IV)
and inhibit DNA re-ligation after enzyme cut, exerting a
rapid bactericidal activity. They are widely used for the
treatment of several community- and hospital-acquired
infections and have become increasingly important also in
resource-limited countries, following the availability of
generics (which have drastically reduced drug costs) and
the remarkable increase of resistance to the oldest and
cheapest antibiotic classes. Resistance to quinolones is an
increasing worldwide problem that challenges the efficacy
of these drugs against several bacterial pathogens and is
known to be strongly associated with quinolone exposure.
Restriction of quinolone consumption has been advocated
as an important tool for the containment of quinolone
resistance and has recently been proved to succeed in
reducing resistance rates in clinical isolates of Escherichia
coli in a community setting from an industrialized country.
This study describes the dissemination of quinolone
resistant E. coli in a very remote community in the Amazon
forest, with a high level isolation and minimal antibiotic
use, not including quinolones. These findings demonstrate
that intervention strategies based only on quinolone
restriction are unlikely to succeed in resource-limited
countries, unless accompanied by measures for reducing
dissemination of resistant isolates by improving sanitation.
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general characteristics and organization of the community) and
from each individual/legal guardian of children included in the
study (about travels outside the community and previous antibiotic
use). For the microbiological investigation, a stool sample was
collected from each individual who consented to participate in the
study, and a fecal swab was obtained from each sample. Moreover,
fecal swabs were obtained from 48 animals reared in the
community, including poultry (n = 19), pigs (n = 13), dogs (n = 8),
cattle (n = 6) and cats (n = 2). Fecal swabs were stored in Amies
transport medium (Oxoid, Milan, Italy) and transferred within
48 hours to the laboratory of Santa Gema Hospital of Yurimaguas.
Screening for Fecal Carriage of Antibiotic Resistant E. coli
Fecal carriage of antibiotic resistant E. coli was investigated by a
direct plating method, as described previously [18–20]. Briefly,
each fecal swab was spread onto a MacConkey Agar No. 3 plate
(MCA) (Oxoid, Milan, Italy) to yield uniform growth, and
antibiotic disks were directly placed onto the seeded plate. After
incubation at 37uC for 12–14 hours, plates were inspected for
coliform growth, and inhibition zone diameters were measured
and interpreted according to the previously described breakpoints
[19,20]. Criteria for differentiating between dominant and
subdominant resistant population were the same as in the previous
survey [19]. Briefly, a growth inhibition zone absent or smaller
than the breakpoint diameter was suggestive of the presence of a
resistant dominant population, while isolated colonies growing
inside a growth inhibition zone of any size were considered
suggestive of the presence of a resistant subdominant population.
Antibiotics tested included ampicillin, ceftriaxone, tetracycline,
trimethoprim-sulfamethoxazole, chloramphenicol, streptomycin,
kanamycin, gentamicin, amikacin, nalidixic acid, and ciprofloxa-
cin (Oxoid).
Characterization of Fluoroquinolone Resistant Isolates
All fecal samples positive for the presence of a coliform
population resistant to ciprofloxacin (17 from humans and 11
from animals) were streaked onto MCA plates supplemented with
5 mg/ml ciprofloxacin (MCA-CIP). One bacterial isolate exhibit-
ing the morphology typical of E. coli was collected from each plate
and identified by the API20E system (bioMe´rieux, Marcy l’E´toile,
France). Susceptibility testing was performed by the disk diffusion
method according to Clinical and Laboratory Standards Institute
(CLSI) [21,22]. E. coli ATCC 25922 was used for quality control
purposes.
Detection of PMQR genes (qnrA, qnrB, qnrC, qnrD, qnrS, aac(69)-
Ib-cr, qepA) was performed by PCR and sequencing, as described
previously [23]. Sequence analysis of gyrA and parC was carried out
as described previously [24]. Nucleotide sequences were deter-
mined on both strands of PCR amplification products at the
Macrogen sequencing facility (Macrogen Inc., Seoul, Korea).
Genotyping of ciprofloxacin resistant isolates was performed by
determination of the main phylogenetic groups (A, B1, B2, D)
Table 1. Characteristics of the study community: 2002 vs. 2009.
2002 2009
General characteristics of the community
Individuals living there 113 140
Households 15 21
Travel time from the nearest urban area (Yurimaguas) 13 hoursa unchanged
Use of water potentially contaminated by other human populations excluded unchanged
Visit by a professional healthcare worker ,every 4 months unchanged
Antimalarial drugs stored yesb none
Antibacterial drugs stored none yesc
Non-human antibiotic use absent unchanged
Features of the study population
Individuals included in the study 89 (79%) 120 (86%)
Households 15 21
Male-to-female ratio 48:41 61:59
Age range (years) 0–59 0–71
Mean age (years) 14.9 17
Median age (years) 9 12
Total no. of travellersd 19 (21%) 33 (27%)
Households with at least one traveller 10 (67%) 15 (71%)
Individuals reporting previous antibiotic usee 3 (3%) 5 (4%)
Households with at least one member reporting antibiotic use 2 (13%) 3 (14%)
Antibiotics used (no. of individuals)f TET (3) AMP (3); SXT (2)
a2-hour drive on a unpaved road, 4-hour motor boat ride, 7-hour walk in the jungle.
bChloroquine and primaquine (introduced following a previous malaria epidemic).
cAmpicillin, dicloxacillin, erythromycin, and trimethoprim-sulfamethoxazole.
dTraveller, an individual with a history of travel to Yurimaguas (the nearest urban area) in the 12 months preceding the survey. No statistically significant difference
between 2002 and 2009 (P.0.37).
eIndividuals reporting antibiotic use in the two weeks preceding the survey. No statistically significant difference between 2002 and 2009 (P=0.76).
fTET, tetracycline; AMP, ampicillin; SXT, trimethoprim-sulfamethoxazole.
doi:10.1371/journal.pntd.0001790.t001
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using the Clermont method [23], Random Amplification of
Polymorphic DNA (RAPD) using the 1290 decamer [23], and
Multi Locus Sequence Typing (MLST) using protocols and
conditions described on the E. coli MLST website [http://mlst.
ucc.ie/mlst/dbs/Ecoli/documents/primersColi_html].
Statistical Analysis
Data entry and analysis were performed with the Epi Info
software package version 2008 (Centers for Disease Control and
Prevention, Atlanta, GA). Statistical differences were determined
by the Chi-Squared test. Confidence intervals were calculated by
Stata Software release 8.0 (StataCorp. 2003).
Results
Characteristics of the Studied Community
Data obtained by the community leader and participants
interviews showed that the characteristics of Angaiza were overall
comparable to those observed in a similar survey carried out in
2002 [18] (Table 1). In particular, no major changes of the
population structure, habits and healthcare organization had
occurred since 2002. The most important difference consisted in
the introduction of a panel of antibacterial drugs to be stored in
the community (absent in 2002), including ampicillin, dicloxacillin,
erythromycin and trimethoprim-sulfamethoxazole. Moreover,
antimalarial drugs were no longer stored in the community,
differently from 2002 when they had been introduced following a
previous malaria epidemic (40% of individuals included in the
2002 study had received chloroquine in the two weeks preceding
the survey [unpublished]).
During the 12 months preceding the survey, 33 individuals
(27.5%) from 15 households had travelled to Yurimaguas (the
nearest urban area), revealing a similar mobility rate compared to
that observed in 2002 (Table 1). As far as antibiotic use is
concerned, in the two weeks preceding the survey antibiotics were
administered to five children (age range 0–5 years) from three
households, for the treatment of diarrheal diseases. In particular,
three children had received ampicillin and two trimethoprim-
sulfamethoxazole (both drugs stored in the community) (Table 1).
Moreover, six individuals reported use of antibiotics in the 12
months preceding the survey (excluding the last two weeks),
although the type of antibiotic could not be identified. Despite the
availability of some antibacterial compounds in the community,
antibiotic use was found to be overall comparable to that observed
in 2002 (P= 0.76 and P= 0.19 for use in the 2 weeks or 12 months
preceding the survey, respectively). The usage of antibiotics for
veterinary, husbandry and agricultural practices, and the use of
animal feed remained totally absent, as they were in 2002.
Fecal Carriage of Antibiotic Resistant E. coli: Emergence
of Quinolone Resistance
Of the 120 individuals included in the 2009 survey, 119 (99%)
were found to carry antibiotic resistant E. coli as part of their
intestinal microbiota (92% in the 2002 survey, P= 0.008).
Compared to the previous survey [18], the most relevant
findings were the overall increase of resistance rates (statistically
significant for ampicillin, trimethoprim-sulfamethoxazole, strepto-
mycin and kanamycin), and the emergence of resistance to
quinolones at remarkable rates (45% to nalidixic acid, 14% to
ciprofloxacin), which was completely absent in 2002 (Table 2). Of
note, quinolone resistant E. coli represented the dominant
enterobacterial population in a considerable proportion of
individuals (Table 2). Carriers of quinolone resistant E. coli were
found in 20 of the 21 households of the community. No significant
association was found between carriage of quinolone resistant
isolates and age, gender, travels to Yurimaguas (or living in a
household with at least one member reporting previous travels to
Yurimaguas) or antibiotic consumption (or living in a household
with at least one member reporting previous antibiotic use) (data
not shown).
Investigation of fecal carriage of antibiotic resistant E. coli in 48
animals reared in the community (including poultry, pigs, cattle,
dogs and cats) showed resistance rates overall similar to that
observed in humans (Table 3). Of note, resistance to quinolones
was widespread in all studied animal species.
Molecular Analysis of Fluoroquinolone Resistant Isolates
of Human and Animal Origin
All 28 ciprofloxacin-resistant E. coli isolates (17 and 11 of human
and animal origin, respectively) were investigated for susceptibility
phenotype, genetic background, and mechanisms of plasmid- and
chromosomal-mediated quinolone resistance.
Ciprofloxacin-resistant isolates were always resistant to nalidixic
acid and usually showed a multidrug resistance phenotype (defined
as resistance to .1 antibiotic class), which mostly included
trimethoprim-sulfamethoxazole (89%), tetracycline (86%), ampi-
cillin (79%), streptomycin (68%), and chloramphenicol (57%)
(Table 4).
An overall genetic heterogeneity was observed among isolates of
either human or animal origin. In fact, they were found to belong
to various phylogenetic groups (61% group A, 28% group B1, and
11% group D), and to 12 different RAPD types (Table 4). The
three most prevalent RAPD types (type A, including 6 isolates
from 3 families; type B, including 6 isolates from 5 families; type
G, including 6 isolates from 4 families) were detected both in
humans and animals and were assigned to ST617, ST10, and
ST224, respectively.
Sequencing the QRDR regions showed the presence of a
double substitution in GyrA (Ser83Leu and Asp87Asn) and a
single substitution in ParC (Ser80Ile) in 27 ciprofloxacin resistant
isolates, and of a double substitution both in GyrA (Ser83Leu and
Asp87Tyr) and ParC (Ser80Ile and Ala108Val) in the remaining
one (Table 4). None of the PMQR genes investigated was
detected.
Discussion
In a previous survey, conducted in 2002, acquired quinolone
resistance was found to be absent in E. coli from the inhabitants of
Angaiza, a very remote community of Chayahuita ethnic group
located in the Peruvian Amazonas and characterized by a
considerable level of geographical isolation, limited contacts with
the exterior, and minimal antibiotic use, which did not include
quinolones [18]. In this study we showed that, despite the
characteristics of the community remained substantially un-
changed over a 7-year period, in 2009 quinolone resistant isolates
were common in Angaiza, with carriage of nalidixic acid and
ciprofloxacin resistant E. coli observed in 45% and 14% of the
studied individuals, respectively. Quinolone resistant E. coli were
also found to be common, at rates similar to those observed in
humans, among animals of different species reared in the
community.
The genetic heterogeneity observed among ciprofloxacin
resistant isolates of human and animal origin excluded that the
emergence of quinolone resistance in Angaiza was the conse-
quence of the occasional introduction into the community of a
highly successful quinolone resistant clone, capable of spreading
and persistence even in the absence of selective pressure. These
Quinolone Resistant E. coli in Remote Amazonas
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findings rather supported the hypothesis of a consistent influx of
resistant isolates into the community, despite remoteness and
limited exchanges with the exterior, with their persistence and
dissemination in the absence of quinolone exposure being favored
by the conditions of poor sanitation confirmed by the finding of
RAPD types shared by humans and animals of different
households. The multidrug resistance phenotype expressed by
most ciprofloxacin resistant isolates would be consistent with a
provenance from urban areas where they are selected by antibiotic
exposure. In fact, the substitutions in the QRDR regions of GyrA
(Ser83Leu and Asp87Asn) and ParC (Ser80Ile) detected in the
ciprofloxacin resistant isolates from Angaiza are known to be
among the most common cause of acquired high level fluoro-
quinolone resistance in clinical isolates of E. coli worldwide [25].
An influx of resistant isolates from urban areas to the remote
community was also hypothesized to explain the high resistance
rates to the oldest antibiotics (i. e. tetracycline, ampicillin,
trimethoprim-sulfamethoxazole, streptomycin and chlorampheni-
col) observed in Angaiza in the 2002 survey [18]. Evidences
supporting this scenario were represented by the similarities of
resistance patterns and resistance genes observed between
Yurimaguas (the nearest urban area) and Angaiza. On that
occasion, the lack of quinolone resistance in the remote
community was thought to reflect the fact that quinolone
resistance rates in Yurimaguas were lower than those to the oldest
antibiotics. In this perspective, the emergence of quinolone
resistance in Angaiza would be consistent with the dramatic
increase of carriage of quinolone resistant E. coli observed among
healthy children in Yurimaguas in the period 2002–2005 (27% vs.
54% and 16% vs. 31% for nalidixic acid and ciprofloxacin,
respectively) [20,26].
In a recent study conducted in very remote villages of rural
Guyana not exposed to quinolones, the finding of ciprofloxacin
resistant E. coli was putatively ascribed to the heavy exposure to
chloroquine, an antimalarial drug that can select for topoisomer-
ase mutations conferring resistance to quinolones [27]. This does
not seem to be the case for the emergence of quinolone resistance
in Angaiza, since this community is located in a malaria endemic
Table 2. Individuals carrying antibiotic resistant E. coli as part of their intestinal microbiota: 2002 vs. 2009.
2002 (n=89) 2009 (n=120) P-value
Total % [CI] Dominant % [CI] Total % [CI] Dominant % [CI] Total (Dominant)
Tetracycline 87 [78–93] 40 [30–51] 93 [87–97] 48 [39–58] NS (NS)
Ampicillin 75 [65–84] 30 [21–49] 99 [95–100] 94 [88–98] ,0.001 (,0.001)
SXT 69 [58–78] 27 [18–37] 99 [95–100] 82 [74–88] ,0.001 (,0.001)
Streptomycin 66 [55–76] 19 [12–29] 98 [93–99] 88 [80–93] ,0.001 (,0.001)
Chloramphenicol 53 [42–63] 18 [11–28] 61 [51–70] 14 [8–22] NS (NS)
Kanamycin 6 [2–13] 0 [0–4] 23 [15–31] 9 [5–16] ,0.001 (0.003)
Gentamicin 1 [0–6] 1 [0–6] 7 [3–13] 1 [0–5] NS (NS)
Amikacin 0 [0–4] 0 [0–4] 0 [0–3] 0 [0–3] NA
Ceftriaxone 0 [0–4] 0 [0–4] 0 [0–3] 0 [0–3] NA
Nalidixic acid 0 [0–4] 0 [0–4] 45 [36–54] 19 [13–27] ,0.001 (,0.001)
Ciprofloxacin 0 [0–4] 0 [0–4] 14 [8–22] 2 [0–6] ,0.001 (NS)
CI, Confidence Intervals; SXT, trimethoprim-sulfamethoxazole; NS, not significant (P.0.05); NA, not applicable. Data of the 2002 survey are from ref. 18.
doi:10.1371/journal.pntd.0001790.t002
Table 3. Animals carrying antibiotic resistant E. coli as part of their intestinal microbiota.
Total (n = 48) Poultry (n =19) Pigs (n=13) Dogs (n =8) Cattle (n =6) Cats (n=2)
n (%, CI) n n n n n
Tetracycline 42 (88, 75–94) 15 13 7 5 2
Ampicillin 42 (88, 75–94) 17 13 8 2 2
SXT 45 (94, 83–98) 17 13 8 5 2
Streptomycin 44 (92, 80–97) 17 12 7 6 2
Chloramphenicol 39 (81, 68–90) 13 13 8 3 2
Kanamycin 6 (13, 6–25) 2 1 3 0 0
Gentamicin 8 (17, 9–30) 5 1 0 2 0
Amikacin 0 (0) 0 0 0 0 0
Ceftriaxone 1 (2, 0–11) 0 0 1 0 0
Nalidixic acid 26 (54, 40–67) 7 10 4 4 1
Ciprofloxacin 11 (23, 13–37) 3 5 2 1 0
CI, Confidence Intervals; SXT, trimethoprim-sulfamethoxazole.
doi:10.1371/journal.pntd.0001790.t003
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area where chloroquine has been used for a long time (e. g. 40% of
individuals included in the 2002 study had received chloroquine in
the two weeks preceding the survey), whilst quinolone resistance
emerged only in recent years. Moreover, data from the 2009
interviews excluded a recent malaria outbreak in Angaiza and
consumption of chloroquine in the two weeks preceding the
survey, ruling out the hypothesis that the differences observed
between 2002 and 2009 could have been related to an increased
exposure to this antimalarial drug.
table-4-captionFluoroquinolones have become increasingly im-
portant in the therapeutic armamentarium of resource-limited
countries, following the availability of generics (which drastically
reduced drug costs) and the dramatic increase of resistance to the
oldest and cheapest antibiotic classes [4,5]. These broad-spectrum,
stable and orally administrable antibiotics have entered among the
first- and second-line choices for the treatment of several common
bacterial infections, including enteric, respiratory and urinary tract
infections, sexually transmitted diseases, as well as serious systemic
infections (e. g. typhoid fever, urinary sepsis, bacteremia in severe
malnutrition) [1,2,5–7]. Due to the frequent unavailability of the
newer and patent protected antibiotics, the dissemination of
fluoroquinolone resistance in resource-limited countries has
worrisome clinical implications.
Acquired quinolone resistance in enterobacteria has been
clearly associated with the use of fluoroquinolones [5,12–14],
being absent or exceedingly rare in remote areas of the planet
away from anthropogenic drug exposure [16,17]. Recently, a
countrywide intervention of quinolone restriction in Israel resulted
in a rapid decrease of resistance rates in clinical isolates of E. coli
[15], suggesting that maintenance of quinolone resistance in
enterobacteria could be strongly dependent on drug exposure.
Our study provided new insights into this phenomenon, as we
demonstrated that quinolone resistant E. coli (likely selected in
urban areas under quinolone selective pressure) were able to
widely disseminate and persist even in very remote settings not
exposed to antibiotics. These findings proved that maintenance of
quinolone resistance in E. coli is not always depended on drug
exposure, as also suggested by recent studies on fitness cost of
quinolone resistance [28,29], and emphasized the key role of the
Table 4. Features of 28 ciprofloxacin resistant E. coli isolates of human and animal origin.
RAPD type
(No of. isolates)
Phylogenetic
group Strain Origin Household
Resistance other than
to quinolones QRDR substitutions
GyrA ParC
A (6) A A2 Human H1 SXT/TET/AMP/S S83L, D87N S80I
A3 Human H1 SXT/TET/AMP/S S83L, D87N S80I
A5 Human H1 SXT/TET/AMP/S S83L, D87N S80I
A6 Human H1 SXT/TET/AMP/S S83L, D87N S80I
A21 Human H3 SXT/TET/AMP/S S83L, D87N S80I
PE001 Dog H17 SXT/TET/AMP/KAN/GEN/CRO S83L, D87N S80I
B (6) A C30 Pig H10 SXT/TET/CHL S83L, D87N S80I
PL003 Chicken H17 SXT/TET/CHL S83L, D87N S80I
C006 Pig H17 SXT/TET/AMP/S/CHL S83L, D87N S80I
A86 Human H15 SXT/TET/AMP/S S83L, D87N S80I
A71 Human H12 SXT/TET/S/CHL S83L, D87N S80I
A105 Human H19 SXT/TET/S/CHL S83L, D87N S80I
C (2) A C021 Pig H3 - S83L, D87N S80I
PE020 Dog H3 - S83L, D87N S80I
D (1) A A75 Human H13 SXT/TET/AMP/S/GEN/CHL S83L, D87N S80I
E (1) A V045 Cow Community TET/AMP S83L, D87N S80I
F (1) A C040 Pig H21 SXT/TET/AMP/S/KAN/CHL S83L, D87N S80I
G (6) B1 A91 Human H16 SXT/TET/AMP/S/GEN S83L, D87N S80I
A4 Human H1 SXT/TET/AMP/S/CHL S83L, D87N S80I
A10 Human H2 SXT/TET/AMP/S/CHL S83L, D87N S80I
A63 Human H10 SXT/TET/AMP/S/CHL S83L, D87N S80I
C031 Pig H10 SXT/TET/AMP/CHL S83L, D87N S80I
PT034 Duck H10 SXT/TET/AMP/CHL S83L, D87N S80I
H (1) B1 A66 Human H11 SXT/TET/AMP/S/CHL S83L, D87N S80I
I (1) B1 A103 Human H19 SXT/TET/AMP/KAN S83L, D87N S80I
L (1) D A101 Human H18 SXT/AMP/S/GEN/CHL S83L, D87N S80I
M (1) D A13 Human H2 SXT/TET/AMP/S/CHL S83L, D87N S80I
N (1) D PL039 Chicken H8 SXT/AMP/S/GEN/CHL S83L, D87Y S80I,
A108V
SXT, trimethoprim-sulfamethoxazole; TET, tetracycline; AMP, ampicillin; S, streptomycin; GEN, gentamicin; CHL, chloramphenicol; CRO, ceftriaxone.
doi:10.1371/journal.pntd.0001790.t004
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intestinal microbiota in the dissemination of such a clinically
relevant antibiotic resistance.
Overall, the results from the present study underline the urgent
need for interventions aimed at improving sanitation and water/
food safety to address the phenomenon of antibiotic resistance in
resource-limited countries. Indeed, unless dissemination of resis-
tant isolates is contained, control strategies based only on
antibiotic restriction policies are unlikely to succeed in those
settings, especially for bacteria able to colonize the human gut.
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